Singapore markets closed

Straits Times Index
3,255.54
+16.51(+0.51%)
S&P 500
3,968.27
-9.26(-0.23%)
Dow
32,467.57
+35.49(+0.11%)
Nasdaq
11,683.37
-85.46(-0.73%)
Bitcoin USD
26,952.38
+68.72(+0.26%)
CMC Crypto 200
590.22
+347.54(+143.21%)

AZN Jul 2023 57.500 put

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

1.0000

0.0000

(0.00%)

As of 10:18AM EDT. Market open.

Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.